IRONWOOD PHARMACEUTICALS, INC. Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Curtailment
IRONWOOD PHARMACEUTICALS, INC. (IRWD) reported Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Curtailment of $2.10 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Income Statement › Other Income
us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments · last filed 2026-02-26
- IRONWOOD PHARMACEUTICALS, INC. defined benefit plan, net periodic benefit cost (credit), gain (loss) due to curtailment for fiscal 2024 was $2.10M.
| Period end | Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Curtailment 12 month |
|---|---|
| 2024-12-31 | $2.10M 10-K · filed 2026-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |